Therapeutic cancer vaccination is becoming a medical reality. In France, biotech company Transgene is leading this revolution by developing individualized vaccines that mobilize the immune system against tumors.
A Changing National Strategy
France is now betting on a vaccination strategy to treat certain cancers, similar to what has been done for infectious diseases. This approach, once experimental, is now supported by solid clinical results and strong political will.
“The potential of vaccination is enormous. We are on the verge of a paradigm shift in how we treat cancer.”
— Prof. Fabrice Barlesi, oncologist and director of Gustave-Roussy
Transgene: A Pioneer in Personalized Immunotherapy
Based in Strasbourg, Transgene develops innovative immunotherapies based on viral vectors, focusing on two main areas: oncolytic viruses and individualized therapeutic vaccines. Its flagship product, TG4050, is the first personalized neoantigen-based vaccine to undergo a randomized study in the adjuvant treatment of head and neck cancers.
At the ASCO 2025 congress, Transgene presented impressive results: no recurrence after two years in treated patients, compared to several relapses in the control group.
“These results strengthen our belief that personalized immunotherapy is the future of cancer treatment.”
— Dr. Alessandro Riva, CEO of Transgene
A Unique Technological Platform: myvac®
The myvac® platform combines the power of the MVA viral vector, artificial intelligence for neoantigen prediction, and a robust bioengineering environment. It enables the design of a tailor-made vaccine for each patient in just a few weeks.
In 2025, Transgene plans to:
– Launch a new clinical trial in a second indication,
– Complete Phase II randomization of TG4050,
– And continue optimizing its manufacturing processes.
A Biotech at the Heart of the French Healthcare Ecosystem
Transgene embodies French excellence in biotechnology, supported by the French Healthcare ecosystem. With its bioengineering capabilities, mastery of viral vectors, and production infrastructure, it is a key player in the new national cancer strategy.
